Dual Pathway Inhibition versus Dual Antiplatelet Therapy in Patients with Acute or nonacute Limb Ischemia: A Propensity Score-Matched Analysis from the RESOLVE Study.
OBJECTIVE Real-world evidence comparing dual-pathway inhibition (DPI) with dual antiplatelet therapy (DAPT) after endovascular revascularization for acute or nonacute limb ischemia is limited. This study aims to compare the 24-month effectiveness and safety outcomes of DPI versus DAPT in this setting. METHODS This pr...